Ochre Bio
Oxford
About Ochre Bio
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $39.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2022)
- Website: ochre-bio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ochre-bio-90336 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.